ProCE Banner Activity

Biomarker Testing and Clinical Trial Enrollment in NSCLC: Retrospective Analysis of Racial Disparities

Slideset Download
Conference Coverage
Multivariable regression analyses of deidentified health record data showed that Black patients with NSCLC were less likely to receive NGS-based genetic testing or enroll on clinical trials than White patients.

Released: June 15, 2021

Expiration: June 14, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme